Ocular melanoma Market Expected to rise, 2034 | Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline

The Ocular melanoma market growth is driven by factors like increase in the prevalence of Ocular melanoma, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Ocular melanoma market report [https://www.delveinsight.com/report-store/ocular-melanoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Ocular melanoma market size, share, Ocular melanoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Ocular melanoma market size growth forward.

Some of the key highlights from the Ocular melanoma Market Insights Report:

*
Several key pharmaceutical companies, including Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., and others, are developing novel products to improve the Ocular melanoma treatment outlook.

*
In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human study of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy for patients with advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included 25-week median follow-up safety data and newly detailed efficacy results.

*
In April 2024, Iovance Biotherapeutics announced that clinical data for lifileucel in combination with pembrolizumab as a frontline treatment for advanced melanoma, along with translational insights, will be showcased at the 2024 ASCO Annual Meeting.

*
In 2023, the United States held the largest share of the ocular melanoma market within the 7MM, accounting for nearly 60% compared to the EU4, the UK, and Japan. Among the EU4 and the UK, the UK reported the highest ocular melanoma market size, while Spain had the lowest share. Additionally, the United States had the highest number of diagnosed incident cases of ocular melanoma within the 7MM.

*
In the U.S., individuals aged 40-70 years made up approximately 60% of ocular melanoma cases. Among the EU4 and the UK, choroidal melanoma was the most commonly diagnosed form of uveal melanoma, followed by ciliary body and iris melanoma.

*
Ocular melanoma is classified into uveal (about 95% of cases) and non-uveal subtypes. Uveal melanoma includes choroidal, ciliary body, and iris melanoma, while non-uveal melanoma comprises conjunctival melanoma and tumors originating from other ocular sites. The disease predominantly affects older adults, particularly those with fair skin and lighter eye colors. Risk factors include dysplastic nevus syndrome, certain cutaneous nevi, and family histories of systemic or ocular cancers, often linked to genetic mutations such as BAP1, GNAQ, and GNA11.

*
Key industry players, including Aura Biosciences, IDEAYA Biosciences, and TriSalus Life Sciences, are driving innovation in the ocular melanoma treatment landscape. Despite advancements, critical unmet needs persist, including a lack of personalized treatment options and standardized diagnostic procedures. Greater patient participation in clinical trials could further expand treatment possibilities for ocular melanoma.

*
As per DelveInsight analysis, the Ocular melanoma market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Ocular melanoma Market Landscape [https://www.delveinsight.com/sample-request/ocular-melanoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Ocular melanoma Overview

Ocular melanoma is a rare but the most common primary eye cancer in adults. It originates in the eye, typically in the uveal tract, which includes the iris, ciliary body, and choroid. Most cases arise in the choroid, the pigmented tissue beneath the retina. This cancer develops from melanocytes, pigment-producing cells, and has the potential to metastasize, most commonly to the liver.

Though often asymptomatic, ocular melanoma may be detected during routine eye exams. Symptoms, when present, include blurred or diminished vision, peripheral vision loss, dark patches on the sclera, dark spots on the iris, floaters, flashes of light, and changes in pupil shape.

The exact cause remains unclear, but risk factors include fair skin, light-colored eyes, family history of melanoma, abnormal eye growths, age, and skin conditions causing atypical moles. Diagnosis involves tests such as ophthalmoscopy, fundus photography, ultrasound, transillumination, CT, MRI, and sometimes a biopsy.

Once diagnosed, the cancer is staged to determine its extent and guide treatment. Staging involves eye exams, imaging, and tests, using systems like the AJCC TNM and COMS to describe tumor size, location, and spread. Staging helps assess severity, guide treatment, and predict survival outcomes.

Do you know the treatment paradigms for different countries? Download our Ocular melanoma Market Sample Report [https://www.delveinsight.com/sample-request/ocular-melanoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Ocular melanoma Epidemiology Insights

*
In 2023, the United States recorded the highest proportion of diagnosed incident cases of ocular melanoma among the 7MM, accounting for 49.0% of all cases.

*
Within the U.S., the majority of uveal melanoma diagnoses were choroidal, followed by ciliary body and iris melanoma.

Ocular melanoma Epidemiology Segmentation

DelveInsight's Ocular melanoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Ocular melanoma historical patient pools and forecasted Ocular melanoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Ocular melanoma Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Ocular melanoma Prevalence

*
Age-Specific Ocular melanoma Prevalence

*
Gender-Specific Ocular melanoma Prevalence

*
Diagnosed and Treatable Cases of Ocular melanoma

Visit for more @ Ocular melanoma Epidemiological Insights [https://www.delveinsight.com/report-store/ocular-melanoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Ocular melanoma Market Insights:

*
In 2023, the total ocular melanoma market size was approximately USD 340 million across the 7MM, with growth anticipated by 2034 during the study period (2020-2034). The United States held the largest market share in 2023, followed by the United Kingdom. Key players, including Aura Biosciences, IDEAYA Biosciences, and TriSalus Life Sciences, are actively developing therapies for ocular melanoma. The anticipated introduction of emerging therapies and treatments is expected to drive a substantial increase in market size during the forecast period (2024-2034).

Ocular melanoma Market Outlook

The treatment landscape for ocular melanoma varies based on tumor size, location, metastatic status, and the patient's overall health. The primary goals of uveal melanoma treatment are to prevent metastatic spread and preserve the eye while maintaining functional vision.

For primary tumors, treatment options include radiation therapies, such as brachytherapy or proton beam therapy, and surgical enucleation. Local therapies, such as surgical resection, laser therapy, or transpupillary thermotherapy (TTT), are commonly used for smaller tumors. Localized radiation methods like plaque brachytherapy or proton therapy can effectively target and shrink tumors. In cases of large tumors or severe complications, enucleation, involving complete eye removal, may be necessary.

Adjuvant treatments enhance the effectiveness of primary therapies. TTT employs heat to destroy tumors, while photodynamic therapy (PDT) uses a photosensitizing drug activated by laser light to selectively eliminate cancer cells.

Approximately half of ocular melanoma patients develop metastatic disease, most commonly in the liver (~90%), with less frequent spread to the lungs, bones, and skin. Lifelong monitoring is essential, as relapse risk persists indefinitely.

The introduction of systemic therapies, a long-standing unmet need in uveal melanoma, has brought significant advancements. Recent FDA approvals of KIMMTRAK (tebentafusp) and HEPZATO KIT (melphalan/hepatic delivery system) have positively transformed the treatment landscape. Emerging therapies, such as darovasertib combined with crizotinib and belzupacap sarotalocan, are anticipated to further enhance treatment outcomes.

Growing awareness and improved diagnostic methods have contributed to an increase in ocular melanoma diagnoses in recent years. Additionally, ongoing research and clinical trials are expanding the understanding of the disease and paving the way for better diagnostic and therapeutic approaches.

Ocular melanoma Marketed Drugs

*
KIMMTRAK (tebentafusp-tebn): Immunocore

*
HEPZATO KIT (melphalan for Injection/Hepatic Delivery System): Delcath Systems

Ocular melanoma Emerging Drugs

*
Darovasertib (IDE196): IDEAYA Biosciences

*
Belzupacap Sarotalocan (AU-011): Aura Biosciences

Ocular melanoma Key Companies

*
Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., and others

For more information, visit Ocular melanoma Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/ocular-melanoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Ocular melanoma Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Ocular melanoma, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Ocular melanoma epidemiology in the 7MM

*
Ocular melanoma marketed and emerging therapies

*
Ocular melanoma companies

*
Ocular melanoma market drivers and barriers

Table of Contents:

1 Ocular melanoma Market Key Comprehensive Insights

2 Ocular melanoma Market Report Introduction

3 Competitive Intelligence Analysis for Ocular melanoma

4 Ocular melanoma Market Analysis Overview at a Glance

5 Executive Summary of Ocular melanoma

6 Ocular melanoma Epidemiology and Market Methodology

7 Ocular melanoma Epidemiology and Patient Population

8 Ocular melanoma Patient Journey

9 Ocular melanoma Treatment Algorithm, Ocular melanoma Current Treatment, and Medical Practices

10 Key Endpoints in Ocular melanoma Clinical Trials

11 Ocular melanoma Marketed Therapies

12 Ocular melanoma Emerging Therapies

13 Ocular melanoma: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Ocular melanoma

16 Ocular melanoma Market Key Opinion Leaders Reviews

18 Ocular melanoma Market Drivers

19 Ocular melanoma Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Ocular melanoma Epidemiology 2034

DelveInsight's "Ocular melanoma - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Ocular melanoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Ocular melanoma Pipeline 2024

"Ocular melanoma Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ocular melanoma market. A detailed picture of the Ocular melanoma pipeline landscape is provided, which includes the disease overview and Ocular melanoma treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ocular-melanoma-market-expected-to-rise-2034-bristol-myers-squibb-merck-co-inc-novartis-ag-roche-holding-ag-pfizer-inc-astrazeneca-plc-eli-lilly-and-company-bayer-ag-glaxosmithkline]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.